Back to search

Article

Anlotinib maintenance following adjuvant chemotherapy in newly diagnosed stage III–IV patients with epithelial ovarian cancer: a retrospective study

2022-05-19

Abstract excerpt

<h4>Background and Aims: </h4> Anti-angiogenesis therapy with bevacizumab maintenance marginally improved the median progression-free survival (mPFS) of 4.9 months in patients with advanced epithelial ovarian cancer (EOC). Anlotinib, an oral small-molecular anti-angiogenic agent, has been reported to treat platinum-resistant EOC. However, little is known about anlotinib maintenance therapy in newly diagnosed EOC....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
78caa6e7-24a8-5d66-835d-78fe274ebdcf
DOI
10.21203/rs.3.rs-1612791/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anlotinib maintenance following adjuvant chemotherapy in newly diagnosed stage III–IV patients with epithelial ovarian cancer: a retrospective studyDOI 10.21203/rs.3.rs-1612791/v1
Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.Semantic proximity
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity
Comparing efficacy and safety of Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Bayesian network meta-regression analysesSemantic proximity
A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapySemantic proximity
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trialSemantic proximity
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.Semantic proximity
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy.Semantic proximity
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Semantic proximity
The Impact of BRCA Mutation on the Efficacy of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.Semantic proximity
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.Semantic proximity
Efficacy and Safety of Bevacizumab-Containing Therapy in Refractory Advanced Breast Cancer：A Retrospective StudySemantic proximity
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy.Semantic proximity
Select a neighboring publication to make it the new centre.